MedTrace Logo

A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)

NCT00652301 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-08-15

No results posted yet for this study

Summary

To determine the effect of ezetimibe and simvastatin given together, and ezetimibe and simvastatin given alone on intestinal cholesterol absorption.

Conditions

  • Cholesterol

Interventions

DRUG

ezetimibe

ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.

DRUG

Comparator: Placebo (unspecified)

matching placebo tablet. Duration of Treatment 31 Weeks.

DRUG

simvastatin

simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2004-04-30
Completion
2004-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652301 on ClinicalTrials.gov